Skip to main content
. Author manuscript; available in PMC: 2013 Mar 1.
Published in final edited form as: Gynecol Oncol. 2011 Nov 22;124(3):589–597. doi: 10.1016/j.ygyno.2011.11.019

Figure 6. Combinatorial effects of sunitinib and ixabepilone are dependent upon RhoB in HOVTAX2.

Figure 6

A. QPCR of RhoB mRNA levels examining lentiviral shRNA silencing of RhoB. RhoB 839 was the only shRNA that has significant silencing in naïve cells. Data is plotted as fold change as compared to nontarget control ± S.D. *p<0.05 B. QPCR of RhoB mRNA levels using nontarget and RhoB 839 shRNA with 24 hr treatment of sunitinib and ixabepilone in combination shows RhoB remains silenced. C. Cell death analysis of cells treated for 72 hours in combination with nontarget and RhoB 839 silenced cells. Cell death was not significantly induced when treated as compared to DMSO control in RhoB silenced cells. Naïve cells have a 56.8% difference with a 4.5% difference in RhoB silenced cells. Paclitaxel resistant cells have a 17.7% difference with only a 0.2% difference in RhoB silenced cells.